From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Nuformix – “absolutely delighted with the data we've generated”. Er, how’s the balance sheet now?

By Steve Moore | Thursday 18 May 2023

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Pharmaceutical development company Nuformix (NFX) has issued an “Inflammation and Duration of Action Update” on its 'NXP002' development programme, emphasising “absolutely delighted with the data we've generated over recent months - all the results we've achieved are as good as we could have hoped for and are the first results from advanced 'close to patient' IPF and inflammation human tissue disease models”. So what of a current share price response to 0.25p, down more than 7%?
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Van Elle Holdings – a Buy?

Thursday »


Character Group – a Buy?



Ingenta – now a Buy again?



Which PR genius wrote this?

Time left: 03:23:58